Huonslab, a leading Korean biotech company, announced the presentation of preclinical data on its innovative human hyaluronidase platform technology, HyDiffuze, at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) annual meeting in Denver. The presentation highlighted HyDiffuze’s potential to revolutionize subcutaneous drug delivery.
The preclinical study specifically investigated the application of HyDiffuze in enhancing subcutaneous delivery of monoclonal antibodies and antibody-drug conjugates (ADCs).
Huonslab conducted comprehensive pharmacokinetic studies involving 11 monoclonal antibodies and 3 ADCs. The study compared the performance of original drug formulations with formulations incorporating the proprietary HyDiffuze platform.
The results consistently demonstrated that HyDiffuze significantly improved subcutaneous drug delivery.
In vivo experiments using Sprague-Dawley rats revealed that formulations incorporating HyDiffuze increased the area under the curve (AUC), a critical indicator of drug exposure, by 116-162%. Furthermore, the maximum plasma concentration (Cmax) increased by 113-170% compared to the original formulations.
Notably, the study also showed that similar levels of AUC and Cmax could be achieved with HyDiffuze-based formulations even when the antibody dose was reduced by approximately 25%.
These findings suggest that HyDiffuze enhances drug dispersion, overcomes limitations associated with subcutaneous administration, and maintains effective therapeutic exposure even at lower drug dosages. This could lead to reduced side effects and improved patient outcomes.
Huonslab envisions broad applications for the HyDiffuze platform beyond monoclonal antibodies and ADCs, potentially extending to other biologics such as nucleic acid therapeutics, bispecific antibodies, and proteolysis-targeting chimera (PROTAC)-based drugs.
“The HyDiffuze platform presents a compelling opportunity for developing improved subcutaneous formulations across a wide range of drug modalities,” stated a Huonslab official. “We are committed to further expanding its applications and exploring its potential to transform drug delivery.”
jwjeon7625
